If you have been reading about incretin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
== External links == Official website Advanced Drug Delivery Reviews, Interviews, http://media.journals.elsevier.com/content/files/addrmagazine-10132810.pdf https://bioscience.utah.edu/faculty/kopecek/index.php Kopeček] on bioscience.utah.edu
The element emanates naturally from the ground, and some building materials, all over the world, wherever traces of uranium or thorium are found, and particularly in regions with soils containing granite or shale, which have a higher concentration of uranium. Not all granitic regions are prone to high emissions of radon. Being a rare gas, it usually migrates freely through faults and fragmented soils, and may accumulate in caves or water. Owing to its very short half-life (four days for 222Rn), radon concentration decreases very quickly when the distance from the production area increases. Radon concentration varies greatly with season and atmospheric conditions. For instance, it has been shown to accumulate in the air if there is a meteorological inversion and little wind. High concentrations of radon can be found in some spring waters and hot springs. The towns of Boulder, Montana; Misasa; Bad Kreuznach, Germany; and the country of Japan have radium-rich springs that emit radon. To be classified as a radon mineral water, radon concentration must be above 2 nCi/L (74 kBq/m3). The activity of radon mineral water reaches 2 MBq/m3 in Merano and 4 MBq/m3 in Lurisia (Italy). Natural radon concentrations in the Earth's atmosphere are so low that radon-rich water in contact with the atmosphere will continually lose radon by volatilization. Hence, ground water has a higher concentration of 222Rn than surface water, because radon is continuously produced by radioactive decay of 226Ra present in rocks.
== Clinical significance == Variations in the CRHR1 gene is associated with enhanced response to inhaled corticosteroid therapy in asthma. CRF1 triggers cells to release hormones that are linked to stress and anxiety [original reference missing]. Hence CRF1 receptor antagonists are being actively studied as possible treatments for depression and anxiety. Variations in CRHR1 are associated with persistent pulmonary hypertension of the newborn.
== Exhibitions == 1933, 10–30 June, Vision féériques d’Orient (Fantasy Perspectives of the East), Paris, town hall of 13th district 1956, 26 May – June, Festival d’architecture et d’art monumental (Monument Architecture and Art Festival), Grand Palais, Paris. Exhibition of some originals from La Basilique de Sainte Sophie (Αγία Σοφία) de Constantinople (The Basilica of Hagia Sophia of Constantinople). 1999, 2 September – 9 October, Yapı Kredi Cultural Centre, exhibition space of the Sermet Çifter Library, İstiklál Cad. 285, Beyoğlu, Turkey. Exhibition of originals from L’Art Islamique en Orient 1, 2 et 3 (Islamic Art in the East 1, 2 and 3). 2021–2022, Exhibition at the Péra Museum – November 2021 – March 2022 – of several of his originals concerning Ayia-Sophia, Theodora and Constantinople (Istanbul).
== In vivo vs In vitro == In vivo staining (also called vital staining or intravital staining) is the process of dyeing living tissues. By causing certain cells or structures to take on contrasting colours, their form (morphology) or position within a cell or tissue can be readily seen and studied. The usual purpose is to reveal cytological details that might otherwise not be apparent; however, staining can also reveal where certain chemicals or specific chemical reactions are taking place within cells or tissues. In vitro staining involves colouring cells or structures that have been removed from their biological context. Certain stains are often combined to reveal more details and features than a single stain alone. Combined with specific protocols for fixation and sample preparation, scientists and physicians can use these standard techniques as consistent, repeatable diagnostic tools. A counterstain is stain that makes cells or structures more visible, when not completely visible with the principal stain.
Sources: en.wikipedia.org
=== Recovery supplements === Common supplements to help athletes recover from exercising include protein and amino acid supplements. The main use for athletes to take dietary proteins are enhance muscle repair and growth. The intake of protein is a part of the nutrient requirements for the normal athlete and is an important component of exercise training. In addition, it aids in performance and recovery. A 2018 meta-review recommended that individuals may take up to 1.6 g/kg/day of protein with a confidence interval spanning from 1.03 to 2.20 so “it may be prudent to recommend ~2.2 g protein/kg/d for those seeking to maximise resistance training-induced gains in FFM.”. FFM is an abbreviation for fat free mass. Dietary protein intake for well-trained athletes should occur before, during and after physical activity as it is advantageous in gaining muscle mass and strength. In healthy individuals with good kidney function there is no evidence that consuming a high protein diet has any deleterious effects. A bountiful protein diet must be paired with a healthy, well-rounded meal plan and regular resistance exercise. Characteristics of this particular diet include the type of exercise, intensity, duration and carbohydrate values of diet. Post-exercise nutrition is an important factor in a nutrition plan for athletes as it pertains to the recovery of the body. Traditionally, sports drinks such as Gatorade and Powerade, are consumed during and after exercise because they effectively rehydrate the body by refueling the body with carbohydrates, minerals and electrolytes.
The harm from smoking comes from the many toxic chemicals in the natural tobacco leaf and those formed in smoke from burning tobacco. A 2024 study estimated that each cigarette reduces life expectancy by 20 minutes, while other studies estimate that each one reduces life expectancy by about 11 minutes on average. Humans continue to smoke because nicotine, the primary psychoactive chemical in cigarettes, is highly addictive. Cigarettes, like narcotics, have been described as "strategically addictive", with their addictive properties being a core component of the business strategy. About half of smokers die from a smoking-related cause. Smoking harms nearly every organ of the body. Smoking leads most commonly to diseases affecting the heart, liver, and lungs, being a major risk factor for heart attacks, strokes, chronic obstructive pulmonary disease (COPD) (including emphysema and chronic bronchitis), and cancer (particularly lung cancer, cancers of the larynx and mouth, and pancreatic cancer). It also causes peripheral vascular disease and hypertension. The incidence of erectile dysfunction is approximately 85 percent higher in men who smoke compared to men who do not smoke. Children born to women who smoke during pregnancy are at higher risk of congenital disorders, cancer, respiratory disease, and sudden death. Starting smoking earlier in life and smoking cigarettes higher in tar content increases the risk of these diseases.
== Environmental impact == An unexpected negative environmental impact of chelating agents, as DTPA, is their toxicity for the activated sludges in the treatment of Kraft pulping effluents. Most of the DTPA worldwide production (several thousands of tons) is intended to avoid hydrogen peroxide decomposition by redox-active iron and manganese ions in the chlorine-free Kraft pulping processes (total chlorine free (TCF) and environmental chlorine free (ECF) processes). DTPA decreases the biological oxygen demand (BOD) of activated sludges and therefore their microbial activity.
=== Audio and video === Audio of Ian Smith's radio address announcing UDI 2 years of independence, 1967 Rhodesian MoI film (7 mins) on YouTube Rhodesia to Zimbabwe, collection of film clips (6 mins) on YouTube Songs of UDI, 3 songs from 1977 (9 mins) on YouTube
Sources: en.wikipedia.org
Some increases in fentanyl deaths do not involve prescription fentanyl but are related to illicitly made fentanyl that is being mixed with or sold as heroin. In 2017 the death rate increased by more than 100% with 368 overdose-related deaths in British Columbia between January and April 2017.
=== Nutrient sensing === The hexosamine biosynthetic pathway's product, UDP-GlcNAc, is utilized by OGT to catalyze the addition of O-GlcNAc. This pathway integrates information about the concentrations of various metabolites including amino acids, carbohydrates, fatty acids, and nucleotides. Consequently, UDP-GlcNAc levels are sensitive to cellular metabolite levels. OGT activity is in part regulated by UDP-GlcNAc concentration, making a link between cellular nutrient status and O-GlcNAc. Glucose deprivation causes a decline in UDP-GlcNAc levels and an initial decline in O-GlcNAc, but counterintuitively, O-GlcNAc is later significantly upregulated. This later increase has been shown to be dependent on AMPK and p38 MAPK activation, and this effect is partially due to increases in OGT mRNA and protein levels. It has also been suggested that this effect is dependent on calcium and CaMKII. Activated p38 is able to recruit OGT to specific protein targets, including neurofilament H; O-GlcNAc modification of neurofilament H enhances its solubility. During glucose deprivation, glycogen synthase is modified by O-GlcNAc which inhibits its activity.
In their 8 June 2017 press release they also noted that, this was the first time the FDA had taken steps to "remove a currently marketed opioid pain medication from sale due to public health consequences of abuse." By 6 July 2017, Endo International voluntarily complied with the FDA removal request.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.